Lenalidomid Sun

Lenalidomide, the active ingredient in Lenalidomid Sun, is an immunomodulatory imide drug presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), mantle cell lymphoma and follicular lymphoma, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, through full regulatory compliance and quality assurance.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma cells and dysplastic clones. - Multiple Myeloma: reduces disease progression, improves overall survival, and delays the need for further chemotherapy in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): corrects ineffective hematopoiesis, decreases transfusion dependence, and can lead to cytogenetic remission in affected patients. - Mantle Cell Lymphoma: induces tumor regression and prolongs progression‑free survival in patients whose disease has relapsed after prior therapy. - Follicular Lymphoma: provides clinical benefit by achieving partial or complete responses in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Rash: mild skin eruptions or itching. - Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary malignancies: development of new cancers such as acute leukemia.

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risks. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombotic risk: assess for clotting disorders and consider prophylactic anticoagulation. - Renal function: adjust monitoring in patients with impaired kidney function. - Hematologic monitoring: perform regular blood counts to detect cytopenias. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Lenalidomide interacts with several agents; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may lower lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increase bleeding risk; monitor coagulation parameters. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P‑glycoprotein substrates: may alter plasma levels. - Live vaccines: risk of infection due to immunomodulation. - CYP450 inhibitors: potential modest increase in drug concentration.